OnKure Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-60.31	-52.67	-35.31	-29.51
Depreciation & Amortization	0.79	0.66	0.56	0.39
Other Amortization	0.14	0.14	-	-
Loss (Gain) From Sale of Investments	0.05	0.05	-	-
Stock-Based Compensation	8.26	4.53	0.2	0.05
Other Operating Activities	0.12	0.12	-	-
Change in Accounts Payable	-14.52	-5.93	1.71	2.65
Change in Other Net Operating Assets	4.18	1.98	-1.71	-0.53
Operating Cash Flow	-61.29	-51.12	-34.55	-26.95
Capital Expenditures	-0.06	-0.05	-0.25	-1.13
Investment in Securities	15.93	15.93	-	-
Investing Cash Flow	15.86	15.87	-0.25	-1.13
Long-Term Debt Issued	-	6	-	-
Net Debt Issued (Repaid)	-	6	-	-
Issuance of Common Stock	58.89	58.91	0.07	0.34
Other Financing Activities	51.29	51.22	-0.72	-1.38
Financing Cash Flow	110.17	116.13	53.13	26.47
Net Cash Flow	64.74	80.89	18.33	-1.62
Free Cash Flow	-61.36	-51.17	-34.79	-28.09
Free Cash Flow Per Share	-6.12	-14.84	-122.59	-
Levered Free Cash Flow	-35.6	-23.71	-22.69	-
Unlevered Free Cash Flow	-35.67	-23.76	-22.69	-
Change in Working Capital	-10.35	-3.95	0.01	2.12

Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q